Modality
ASO
MOA
AuroraAi
Target
JAK2
Pathway
RNA Splicing
IPF
Development Pipeline
Preclinical
~Feb 2010
→ ~May 2011
Phase 1
~Aug 2011
→ ~Nov 2012
Phase 2
~Feb 2013
→ ~May 2014
Phase 3
~Aug 2014
→ ~Nov 2015
NDA/BLA
~Feb 2016
→ ~May 2017
Approved
Aug 2017
→ Sep 2029
ApprovedCurrent
NCT03631303
2,785 pts·IPF
2018-05→TBD·Not yet recruiting
NCT06129024
2,893 pts·IPF
2017-08→TBD·Terminated
NCT07988923
1,628 pts·IPF
2024-02→2026-06·Completed
+1 more trial
7,602 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2026-06-032mo awayPh3 Readout· IPF
2029-09-273.5y awayPh3 Readout· IPF
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Termina…
Approved
Not yet…
Approved
Not yet…
Approved
Complet…
Catalysts
Ph3 Readout
2026-06-03 · 2mo away
IPF
Ph3 Readout
2029-09-27 · 3.5y away
IPF
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03631303 | Approved | IPF | Not yet recr... | 2785 | 6MWD |
| NCT06129024 | Approved | IPF | Terminated | 2893 | MRD |
| NCT07988923 | Approved | IPF | Completed | 1628 | PFS |
| NCT06268975 | Approved | IPF | Not yet recr... | 296 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |